3 Growth Stocks With At Least 33% Earnings Growth
Bond yields are sitting near their highest levels since 2007, which puts pressure on weaker businesses as borrowing costs stay elevated. Stronger companies with healthy balance sheets and solid earnings potential may be better placed to handle this tougher backdrop. That is where this high growth potential screen comes in. This article highlights three stocks from that list that analysts expect to deliver robust earnings growth.
The three shares highlighted below are just a small sample, with the full screen surfacing 285 more companies with similarly strong earnings profiles and financial footing that are not covered here.
If you want to move beyond this short list and quickly identify candidates that fit your own risk and return preferences, head straight into the Healthy high growth potential screener to filter, analyze and pinpoint your highest conviction ideas.
Broadcom (AVGO)
Overview: Broadcom supplies high-performance semiconductor components and infrastructure software that power data centers, AI workloads, networking, storage, and enterprise private cloud environments.
Operations: Broadcom generates about US$59.4b from Semiconductor Solutions and roughly US$29.7b from Infrastructure Software, reflecting a hardware and software centric model.
Market Cap: US$1,694.6b
Broadcom matters for this Healthy high growth potential screen because its AI focused semiconductor solutions plug directly into the build out of data-center computing and networking capacity.
"Broadcom is generating substantial free cash flow, expanding its custom silicon business, strengthening its position in networking, and integrating software assets that further diversify earnings."
The key consideration is how evolving demand patterns for AI infrastructure ultimately influence pricing power and future margin strength.
Those margin swings sit at the center of the full narrative for Broadcom, which maps how Broadcom’s AI cash flows, capital returns and concentration risks could evolve from here.
Amylyx Pharmaceuticals (AMLX)
Overview: Amylyx Pharmaceuticals develops oral and injectable therapies for rare endocrine and neurodegenerative conditions, with late stage assets supporting its high growth potential theme link.
Market Cap: US$3.8b
Amylyx Pharmaceuticals matters for this Healthy high growth potential screen because its late stage rare disease pipeline could transform forecast earnings if key programs clear their final hurdles.
"Advancement of avexitide as a potential first approved therapy for post bariatric hypoglycemia, supported by five prior PBH trials and a fully recruited pivotal Phase III LUCIDITY study with top line data expected in Q3 2026, could open a new rare disease revenue stream if outcomes support approval and reimbursement."
What happens to Amylyx Pharmaceuticals’ long term growth story may hinge on how one unresolved piece of the commercial puzzle ultimately falls into place.
That unresolved piece is precisely where the full narrative for Amylyx Pharmaceuticals steps in, unpacking how trial risk, pricing power and rare disease adoption could accelerate or stall the story of Amylyx Pharmaceuticals.
Palantir Technologies (PLTR)
Overview: Palantir Technologies builds data and AI platforms like Foundry that help governments and enterprises turn complex information into operational decisions.
Operations: Palantir generates about US$3.2b from Government customers and roughly US$2.9b from Commercial clients, with most revenue coming from the United States.
Market Cap: US$460.9b
Palantir Technologies fits this Healthy high growth potential theme because its Foundry and AI platforms aim to convert data sprawl into scalable, higher margin software deployments for both government and commercial clients, which is the type of earnings engine this screen is designed to identify.
"The balance sheet tells a different story: the company has zero debt and significant cash, so that model rewarded it heavily and gave a fair value close to $925."
What happens if a single key assumption about how quickly enterprises adopt AI-powered Foundry workflows shifts even slightly in either direction?
If that adoption curve is what matters most for you, the full narrative for Palantir Technologies shows where Palantir Technologies could be accelerating, stalling or quietly decoupling expectations.
Seeking Alternatives Before The Crowd?
Fresh ideas move fast. Breakout themes gain momentum, early information gets stale, and under the radar for now opportunities can be caught dropping out of reach. Consider acting while ideas are still developing.
- Spot cash rich compounders by scanning the list of solid balance sheet and fundamentals (23 results) and focus your attention on businesses with money to reinvest while it matters.
- Track income engines that keep paying by using the 7 dividend fortresses and identify high yielders before everyone focuses on the same payouts.
- Explore companies involved in artificial intelligence with the 37 profitable AI stocks that aren't just burning cash and concentrate on firms that are already reporting earnings related to AI activity.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com